Free Research Report as Phibro Animal Health’s Sales Jumped7%; Adjusted EPS Advanced 12.8%

Stock Monitor: AAC Holdings Post Earnings Reporting

LONDON, UK / ACCESSWIRE / February 28, 2018 / Active-Investors.com has just released a free earnings report on Phibro Animal Health Corp. (NASDAQ: PAHC) (“Phibro”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=PAHC. Phibro reported its second quarter fiscal 2018 operating and financial results on February 05, 2018. The maker of animal health products and nutritional supplements outperformed top- and bottom-line expectations. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for AAC Holdings, Inc. (NYSE: AAC), which also belongs to the Healthcare sector as the Company Phibro Animal Health. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=AAC

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Phibro Animal Health most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=PAHC

Earnings Highlights and Summary

Phibro’s net sales of $205.9 million for the three months ended December 31, 2017, increased 7% compared to net sales of $191.6 million in Q2 FY17. The Company’s reported numbers exceeded analysts’ expectations by $11.11 million.

During Q2 FY18, Phibro’s gross profit of $66.9 million, jumped 5% from $63.5 million in Q2 FY17. The Company’s gross profit decreased to 32.5% of net sales for the reported quarter compared to 33.1% for the prior year’s same quarter. Phibro’s Q2 FY18 results included $1.4 million of acquisition-related cost of goods sold.

For Q2 FY18, Phibro’s selling, general, and administrative expenses (SG&A) of $43.0 million, increased 5% from $40.9 million in Q2 FY17. The Company’s SG&A for the reported quarter included $1.7 million in costs relating to the partial settlement of the pension plan. For Q2 FY18, Phibro’s adjusted EBITDA of $32.5 million grew 4% compared to $31.2 million in Q2 FY17.

Phibro’s net income was $7.0 million, or $0.17 per diluted share, for Q2 FY18 compared to net income of $13.4 million, or $0.34 per diluted share, for Q2 FY17. The decrease in earnings was primarily due to a $8.3 million increase in income tax expense.

Phibro’s adjusted earnings were $0.44 per share for Q2 FY18, up 12.8% compared to $0.39 per share in Q2 FY17. Higher gross profit, lower interest expense, net, and a lower effective income tax rate were the primary contributors to the improvement. The Company’s earnings beat Wall Street’s estimates of $0.39 per share.

Phibro Animal Health’s Segment Results

During Q2 FY18, the Animal Health segment’s net sales of $132.8 million advanced 7% compared to $123.7 million in Q2 FY17, primarily due to volume increases across all product groups within the segment. Within the Animal Health division, Nutritional specialty products jumped 12% to $32.6 million on a y-o-y basis, primarily due to volume growth of its products for the dairy and poultry industries in the United States and by penetration into various international countries. The segment’s Vaccines sales rose 7% to $18.2 million, primarily due to volume growth in international markets. The segment’s MFA sales gained 6% to $82.0 million.

Excluding the effects of the acquisition-related cost of goods sold, Animal Health’s gross profit increased $3.9 million on a y-o-y basis due to volume growth, higher average selling prices on selected products, and lower unit costs from improved operating efficiencies. Animal Health’s adjusted EBITDA for the reported quarter edged up 1% to $35.0 million on a y-o-y basis, due to sales growth and increased gross profit.

For Q2 FY18, the Mineral Nutrition segment’s net sales totaled $59.6 million reflecting growth of 5% compared to $56.7 million in Q2 FY17. The increased revenue was due to favorable product mix, plus higher average selling prices resulting from underlying raw material commodity price increases. Mineral Nutrition gross profit increased $0.9 million on a y-o-y basis due to favorable product mix and higher average selling prices. Mineral Nutrition adjusted EBITDA advanced 18% to $5.6 million on a y-o-y basis.

During Q2 FY18, the Performance Products segment’s net sales surged 19% to $13.4 million compared to $11.2 million in Q2 FY17, due to higher average selling prices of copper-based products and higher volumes of copper-based and personal care products. The segment’s adjusted EBITDA was similar to the prior year’s same quarter at $0.3 million as higher volumes and selling prices were offset by higher product costs.

Cash Matters

Phibro had $67 million cash and short-term investments on hand at December 31, 2017. The Company had 2.6x leverage ratio at December 31, 2017, with total debt of $318 million.

Stock Performance Snapshot

February 27, 2018 – At Tuesday’s closing bell, Phibro’s stock was slightly down 0.52%, ending the trading session at $38.55.

Volume traded for the day: 156.06 thousand shares, which was above the 3-month average volume of 106.34 thousand shares.

Stock performance in the last month – up 7.53%; previous three-month period – up 11.26%; past twelve-month period – up 35.74%; and year-to-date – up 15.07%

After yesterday’s close, Phibro’s market cap was at $1.53 billion.

Price to Earnings (P/E) ratio was at 22.58.

The stock has a dividend yield of 1.04%.

The stock is part of the Healthcare sector, categorized under the Specialized Health Services industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 491161